Related Experiment Video
Updated: Jul 16, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Amiodarone induced pulmonary fibrosis--a clinical case report]
Marta N Silva1, Patrícia Bacellar, Helena Martins
1Serviço de Pneumologia, Hospital de São João de Deus, 4761-917 V.N. Famalicão.
Abstract:
Amiodarone is an antiarrhytmic drug and it is used to treat supraventricular or ventricular rhythm disturbances. Nevertheless it is not free of side effects. Amiodarone-induced pulmonary toxicity is one of them and is relatively rare (5 to 10% of cases) and can be fatal. There are several cumulative factors that may enhance susceptibility to pulmonary toxicity, such as advanced age and pre-existing pulmonary dysfunction. We present a case study of amiodarone-induced toxicity (pulmonary fibrosis) in an 81-year-old man. The patient had been treated with amiodarone for five years in daily dose 200 mg/day. After withdrawing the drug and systemic corticosteroid therapy, clinical, functional and radiological improvement was observed. This case confirms the needs of a vigilant monitoring and early diagnosis of the adverse effects of amiodarone therapy, and the difficulty of diagnosing it due to the nonspecificity of symptoms, clinical findings, and test results.
Related Concept Videos
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
